Raymond James Financial’s Neurocrine Biosciences NBIX Stock Holding History

Raymond James Financial’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$97.8M	Sell	580,170 -21,317	-4%	-$3.16M	0.03%	577
2026 Q1	$78.3M	Sell	601,487 -29,935	-5%	-$3.97M	0.02%	615
2025 Q4	$89.2M	Buy	631,422 +64,485	+11%	+$9.34M	0.03%	553
2025 Q3	$79.6M	Sell	566,937 -224,589	-28%	-$30.4M	0.03%	575
2025 Q2	$99.5M	Sell	791,526 -956	-0.1%	-$110K	0.03%	482
2025 Q1	$87.6M	Sell	792,482 -51,420	-6%	-$6.51M	0.03%	476
2024 Q4	$115M	Buy	+843,902	New	+$104M	0.04%	387

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Raymond James Financial's NBIX Position: Q2 2026 in Review

Raymond James Financial reduced its Neurocrine Biosciences (NBIX) stake by 3.5% in Q2 2026, selling an estimated $3.16M and leaving 580,170 shares worth $97.8M. The position accounts for 0.03% of the portfolio, ranked #577.

Raymond James Financial first reported a position in NBIX in Q4 2024 and has held it in 7 quarters since. The position peaked at $115M in Q4 2024. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Raymond James Financial held 580,170 shares of Neurocrine Biosciences worth $97.8M as of Q2 2026.
Raymond James Financial sold 21,317 Neurocrine Biosciences shares in Q2 2026, an estimated $3.16M.
Neurocrine Biosciences made up 0.03% of Raymond James Financial's portfolio in Q2 2026, its #577 holding.
Raymond James Financial first reported a position in Neurocrine Biosciences in Q4 2024 and has held it in 7 quarters since.
Raymond James Financial's Neurocrine Biosciences position peaked at $115M in Q4 2024.
781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.